Cargando…
Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1 hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced by high-frequency stimulation (HFS), in slices from Ts65Dn mice compare...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914153/ https://www.ncbi.nlm.nih.gov/pubmed/29849573 http://dx.doi.org/10.1155/2018/9235796 |
_version_ | 1783316661373239296 |
---|---|
author | Scott-McKean, Jonah J. Roque, Adriano L. Surewicz, Krystyna Johnson, Mark W. Surewicz, Witold K. Costa, Alberto C. S. |
author_facet | Scott-McKean, Jonah J. Roque, Adriano L. Surewicz, Krystyna Johnson, Mark W. Surewicz, Witold K. Costa, Alberto C. S. |
author_sort | Scott-McKean, Jonah J. |
collection | PubMed |
description | The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1 hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced by high-frequency stimulation (HFS), in slices from Ts65Dn mice compared with euploid mouse-derived slices. Additionally, therapeutically relevant doses of the drug memantine were shown to rescue learning and memory deficits in Ts65Dn mice. Here, we observed that 1 μM memantine had no detectable effect on HFS-induced LTP in either Ts65Dn- or control-derived slices, but it rescued TBS-induced LTP in Ts65Dn-derived slices to control euploid levels. Then, we assessed LTP induced by four HFS (4xHFS) and found that this form of LTP was significantly depressed in Ts65Dn slices when compared with LTP in euploid control slices. Memantine, however, did not rescue this phenotype. Because 4xHFS-induced LTP had not yet been characterized in Ts65Dn mice, we also investigated the effects of picrotoxin, amyloid beta oligomers, and soluble recombinant human prion protein (rPrP) on this form of LTP. Whereas ≥10 μM picrotoxin increased LTP to control levels, it also caused seizure-like oscillations. Neither amyloid beta oligomers nor rPrP had any effect on 4xHFS-induced LTP in Ts65Dn-derived slices. |
format | Online Article Text |
id | pubmed-5914153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-59141532018-05-30 Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome Scott-McKean, Jonah J. Roque, Adriano L. Surewicz, Krystyna Johnson, Mark W. Surewicz, Witold K. Costa, Alberto C. S. Neural Plast Research Article The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1 hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced by high-frequency stimulation (HFS), in slices from Ts65Dn mice compared with euploid mouse-derived slices. Additionally, therapeutically relevant doses of the drug memantine were shown to rescue learning and memory deficits in Ts65Dn mice. Here, we observed that 1 μM memantine had no detectable effect on HFS-induced LTP in either Ts65Dn- or control-derived slices, but it rescued TBS-induced LTP in Ts65Dn-derived slices to control euploid levels. Then, we assessed LTP induced by four HFS (4xHFS) and found that this form of LTP was significantly depressed in Ts65Dn slices when compared with LTP in euploid control slices. Memantine, however, did not rescue this phenotype. Because 4xHFS-induced LTP had not yet been characterized in Ts65Dn mice, we also investigated the effects of picrotoxin, amyloid beta oligomers, and soluble recombinant human prion protein (rPrP) on this form of LTP. Whereas ≥10 μM picrotoxin increased LTP to control levels, it also caused seizure-like oscillations. Neither amyloid beta oligomers nor rPrP had any effect on 4xHFS-induced LTP in Ts65Dn-derived slices. Hindawi 2018-04-10 /pmc/articles/PMC5914153/ /pubmed/29849573 http://dx.doi.org/10.1155/2018/9235796 Text en Copyright © 2018 Jonah J. Scott-McKean et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Scott-McKean, Jonah J. Roque, Adriano L. Surewicz, Krystyna Johnson, Mark W. Surewicz, Witold K. Costa, Alberto C. S. Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome |
title | Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome |
title_full | Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome |
title_fullStr | Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome |
title_full_unstemmed | Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome |
title_short | Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome |
title_sort | pharmacological modulation of three modalities of ca1 hippocampal long-term potentiation in the ts65dn mouse model of down syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914153/ https://www.ncbi.nlm.nih.gov/pubmed/29849573 http://dx.doi.org/10.1155/2018/9235796 |
work_keys_str_mv | AT scottmckeanjonahj pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome AT roqueadrianol pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome AT surewiczkrystyna pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome AT johnsonmarkw pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome AT surewiczwitoldk pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome AT costaalbertocs pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome |